BofA Securities analyst Charlie CY Yang initiates coverage on $AbbVie (ABBV.US)$ with a hold rating.
According to TipRanks data, the analyst has a success rate of 71.4% and a total average return of 12.3% over the past year.
Furthermore, according to the comprehensive report, the opinions of $AbbVie (ABBV.US)$'s main analysts recently are as follows:
Ahead of the anticipated data readout for AbbVie and Cerevel's emraclidine in Q4, there is significant discussion among investors regarding the potential results of the EMPOWER-1 and EMPOWER-2 Phase 2 trials, particularly considering the recent approval of Bristol Myers' KarXT and data from Neurocrine's Phase 2 NBI-568. While expectations are for emraclidine's efficacy to be comparable to KarXT, the latest data from NBI-568 have introduced some concerns about the chance of emraclidine not performing as well as KarXT in its pivotal trials. Nevertheless, there remains a positive outlook for the upcoming readout, with a more favorable valuation being considered for AbbVie.
The substantial growth levers within AbbVie's portfolio, notably Skyrizi and Rinvoq, are now recognized for their importance. Despite this recognition, consensus forecasts for Q3 seemed to underappreciate the growth observed from prescriptions during the quarter and in prior periods.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美銀證券分析師Charlie CY Yang首次給予$艾伯維公司 (ABBV.US)$持有評級。
根據TipRanks數據顯示，該分析師近一年總勝率為71.4%，總平均回報率為12.3%。
此外，綜合報道，$艾伯維公司 (ABBV.US)$近期主要分析師觀點如下：
在艾伯維公司和Cerevel的emraclidine Q4的預期數據披露之前，投資者之間就EMPOWER-1和EMPOWER-2階段2試驗的潛在結果展開了重要討論，特別是考慮到Bristol Myers的KarXt的最新批准和來自Neurocrine階段2 NBI-568的數據。雖然人們期望emraclidine的療效與KarXt相當，但NBI-568的最新數據引發了一些擔憂，即emraclidine在關鍵試驗中表現可能不如KarXt。儘管如此，人們對即將公佈的數據持樂觀態度，對艾伯維公司的估值更爲有利。
艾伯維公司組合中的重要增長動力，特別是Skyrizi和Rinvoq，現在被認爲非常重要。儘管有這一認識，Q3的共識預測似乎低估了該季度和之前期間處方增長所觀察到的增長。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
